Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Molecular Targeted Agents / Immunotherapy /

113 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Molecular Targeted Agents / Immunotherapy / Biologics

    Multiple Myeloma

    VICCHEM1470

    11/05/2014

    Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Gastric/Gastroesophageal
    Liver
    Lung

    VICCPHI15114

    09/28/2016

    An Open-Label, Multicenter, Phase 1 study of Ramucirumab plus MEDI4736 in Patients with Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia
    Myelodysplastic Syndrome

    VICCHEM1660

    09/27/2016

    A Phase 1 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    VICCTHO1602

    09/23/2016

    An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia
    Multiple Myeloma

    VICCHEM1621

    09/16/2016

    An Open-Label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-Tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY 1251152 in Patients with Advanced Hematological Malignancies

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Small Cell

    VICCTHO1603

    09/15/2016

    A Phase 2 Study of LY2606368 in Patients with Extensive Stage Disease Small Cell Lung Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia

    VICCHEM1654

    09/09/2016

    An Open-Label, Multi-Center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients with Newly Diagnosed FMS-Like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who are Eligible for Standard Induction and Consolidation Chemotherapy

    Molecular Targeted Agents / Immunotherapy / Biologics

    Kidney (Renal Cell)
    Lung
    Melanoma
    Miscellaneous
    Non Small Cell
    Uterine

    VICCPHI1634

    08/30/2016

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects with Advanced or Metastatic Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE15120

    08/18/2016

    Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor-Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II Study with Pharmacodynamic Markers (TBCRC035)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Sarcoma

    COGARST1431

    08/18/2016

    A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lymphoma

    ECOGHEME4412

    08/18/2016

    A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Bones and Joints

    COGAOST1521

    08/09/2016

    A Phase 2 Study of GPNMB-targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; IND# 128248, NSC# 763737), in Recurrent or Refractory Osteosarcoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    VICCTHO1614

    08/05/2016

    A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast
    Lung
    Non Small Cell
    Ovarian
    Pancreatic

    VICCPHI1671

    08/02/2016

    A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Hematologic

    VICCHEM1613

    08/02/2016

    A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction

    Molecular Targeted Agents / Immunotherapy / Biologics

    Adrenocortical
    Lung
    Sarcoma
    Wilms / Other Kidney (Pediatrics)

    COGADVL1522

    08/02/2016

    A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953, NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Pancreatic

    ECOGGIEA2131

    07/28/2016

    A Phase I and Randomized, Double-Blinded Phase II Study of nab-Paclitaxel/Gemcitabine plus AZD1775 or Placebo in Treatment-Naive Metastatic Adenocarcinoma of the Pancreas

    Molecular Targeted Agents / Immunotherapy / Biologics

    Hematologic
    Leukemia
    Lung
    Miscellaneous
    Small Cell

    VICCHEMP1615

    07/21/2016

    A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects with Advanced Malignancies

    Molecular Targeted Agents / Immunotherapy / Biologics

    Neuro-Oncology

    VICCNEU15105

    07/15/2016

    A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Bladder
    Urologic

    VICCURO15119

    06/14/2016

    Phase II Trial of Palbociclib (PD-0332991) in Patients with Metastatic Urothelial Cancer (UC) after Failure of First-Line Chemotherapy

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lymphoma
    Miscellaneous

    VICCPHI1616

    06/08/2016

    A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung

    VICCTHO15129

    06/07/2016

    XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    VICCTHO1625

    06/01/2016

    An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as First Line-Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Kidney (Renal Cell)

    VICCURO15127

    06/01/2016

    A Randomized Phase 2 Trial of AXITINIB and TRC105 versus AXITINIB Alone (Including a Lead-In Phase 1B Dose-Escalation Portion) in Patients with Advanced or Metastatic Renal Cell Carcinoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Small Cell

    VICCTHO15117

    05/19/2016

    A Phase 2 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line Treatment of Patients with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Carcinoma (TRINITY)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Melanoma

    ECOGMELEA6141

    05/10/2016

    Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia

    VICCHEM15113

    05/06/2016

    A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

    Molecular Targeted Agents / Immunotherapy / Biologics

    VICCBMT1465

    05/05/2016

    A Phase II , Randomized, Double-blind, Placebo-Controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects with Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

    Molecular Targeted Agents / Immunotherapy / Biologics

    Bladder
    Colon
    Gastric/Gastroesophageal
    Kidney (Renal Cell)
    Rectal
    Urologic

    VICCGI15126

    05/03/2016

    A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia
    Lymphoma
    Pediatric Leukemia
    Pediatric Lymphoma

    VICCPED1537

    04/28/2016

    T2014-001 A Phase I Trial of Temsirolimus (CC-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia
    Pediatric Leukemia

    COGAAML1331

    04/28/2016

    A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    ECOGTHOS1403

    04/26/2016

    A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Multiple Myeloma

    VICCBMT1566

    04/21/2016

    Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1599

    04/11/2016

    A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Sarcoma

    COGAOST1321

    04/07/2016

    Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1587

    04/05/2016

    An Open-Label, First -in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Colon
    Head/Neck
    Liver
    Lung
    Miscellaneous
    Neuro-Oncology
    Rectal
    Sarcoma
    Thyroid

    VICCMD15110

    04/05/2016

    A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Small Cell

    VICCTHO1595

    03/25/2016

    An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy

    Molecular Targeted Agents / Immunotherapy / Biologics

    Head/Neck

    VICCHN1574

    03/21/2016

    A Randomized, Multicenter, Double-Blind Phase 2 Study of Palbociclib plus Cetuximab versus Cetuximab for the Treatment of Human Papillomavirus -Negative, Cetuximab-Naive Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck After Failure of One Prior Platinum-Containing Chemotherapy Regimen

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1562

    03/15/2016

    SOLAR-1: A Phase III Randomized Double-Blind, Placebo Controlled Study of Alpelisib in combination with Fulvestrant for Men and Postmenopausal Women with Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer which Progressed on or After Aromatase Inhibitor Treatment

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1557

    03/11/2016

    A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) with Paclitaxel in Patients with Triple Negative Metastatic Breast Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Hematologic

    VICCHEM1580

    03/11/2016

    A Phase 2, Prospective Study of PRM-151 in Subjects with Primary Myelofibrosis (PMF), Post - Polycythemia Vera MF (post-PV MF), or Post -Essential Thrombocythemia MF (post-ET MF)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1462

    03/08/2016

    A Phase I Dose Escalation Study of POL6326 with Eribulin in Patients with Relapsed Metastatic Breast Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Colon
    Head/Neck
    Lung
    Lymphoma
    Melanoma
    Non Small Cell
    Ovarian
    Rectal

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia

    VICCHEM1597

    02/17/2016

    A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1552

    02/02/2016

    A Randomized Phase II Study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia
    Pediatric Leukemia

    COGAALL1331

    02/01/2016

    Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    VICCTHO1573

    02/01/2016

    An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Multiple Myeloma

    VICCHEM15112

    01/11/2016

    A Phase 1/2 Open-label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed/Refractory Multiple Myeloma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Neuroblastoma (Pediatrics)

    VICCPED1489

    01/07/2016

    Molecular-Guided Therapy for the Treatment of Patients with Relapsed and Refractory Childhood Cancers

    Molecular Targeted Agents / Immunotherapy / Biologics

    Hematologic

    VICCHEM1565

    01/05/2016

    A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis

    Molecular Targeted Agents / Immunotherapy / Biologics

    Gastric/Gastroesophageal

    VICCGI1515

    01/05/2016

    A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Neuro-Oncology

    ECOGNEUA071102

    12/18/2015

    A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation

    Molecular Targeted Agents / Immunotherapy / Biologics

    Neuro-Oncology

    ECOGNEUA071401

    12/18/2015

    Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast - Female

    VICCBRE14101

    12/04/2015

    Phase I/II Study of BYL719 and Nab-Paclitaxel in Patients with Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Sarcoma

    COGAEWS1221

    12/02/2015

    Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1546

    12/01/2015

    The Impact of HER2 Heterogeneity on the Treatment of Early- Stage HER2-Positive Breast Cancer: A Phase II Study of T- DM1 in Combination with Pertuzumab in the Preoperative Setting

    Molecular Targeted Agents / Immunotherapy / Biologics

    Melanoma

    ECOGMELS1404

    12/01/2015

    A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Bladder
    Breast
    Colon
    Esophageal
    Gastric/Gastroesophageal
    Gynecologic
    Head/Neck
    Kidney (Renal Cell)
    Lung
    Melanoma
    Non Small Cell
    Pancreatic
    Rectal
    Urologic
    Uterine

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Multiple Myeloma

    VICCHEM14131

    11/17/2015

    Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lymphoma

    VICCHEM14125

    11/13/2015

    A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Colon
    Esophageal
    Gastric/Gastroesophageal
    Liver
    Pancreatic
    Rectal

    VICCGIP1536

    10/26/2015

    A Phase 1 Study of Alisertib (MLN8237) in combination with mFOLFOX in Gastrointestinal Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Bladder
    Breast
    Hematologic
    Leukemia
    Lymphoma
    Multiple Myeloma
    Myelodysplastic Syndrome
    Pancreatic
    Urologic

    VICCHEMP1558

    10/09/2015

    A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung

    VICCTHO1519

    10/07/2015

    A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti−PDL1 Antibody) Compared with Cisplatin or Carboplatin+Pemetrexed for PD-L1−Selected Chemotherapy Naive Patients with Stage Iv Non-Squamous Non−Small Cell Lung Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1543

    09/30/2015

    A Phase III, Multicenter, Randomized, Placebo-Controlled Study of MPDL3280A (Anti−PD-L1 Antibody) in Combination with Nab-Paclitaxel Compared with Placebo with Nab-Paclitaxel for Patients with Previously Untreated Metastatic Triple -Negative Breast Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Multiple Myeloma

    VICCHEM1437

    09/29/2015

    A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    ECOGTHOE4512

    09/15/2015

    A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1692

    09/01/2015

    Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast
    Lung
    Pancreatic

    VICCPHI1528

    07/22/2015

    A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Other

    ECOGEAY131-M

    07/16/2015

    Molecular Analysis for Therapy Choice

    Molecular Targeted Agents / Immunotherapy / Biologics

    Pediatric Lymphoma

    COGAHOD1331

    07/15/2015

    A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Small Cell

    VICCTHO1510

    07/09/2015

    A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Pancreatic

    VICCGI1507

    06/16/2015

    NAB-PACLITAXEL (ABRAXANE) plus Gemcitabine in Subjects with Locally Advanced Pancreatic Cancer (LAPC): An International, Open-Label, Multi-Center, Phase 2 Study (LAPACT)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1374

    06/15/2015

    Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination with Enzalutamide in Patients with Androgen Receptor Positive Triple Negative Metastatic Breast Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    VICCHEMP14114

    05/20/2015

    A Phase 1, Open-label, Multicenter, Randomized, 2-Period Crossover Study to Evaluate the Bioequivalence of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia
    Lymphoma
    Pediatric Leukemia
    Pediatric Lymphoma

    COGAALL1231

    05/13/2015

    A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia

    VICCHEM1505

    05/06/2015

    An Open-Label Phase I Dose-Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1143572 given in a Once-Daily or an Intermittent Dosing Schedule in Subjects with Advanced Acute Leukemia

    Molecular Targeted Agents / Immunotherapy / Biologics

    Soft Tissue

    COGARST1321

    04/21/2015

    Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC#737754, IND# 118613)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    ECOGTHOS1400

    04/02/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1480

    03/31/2015

    A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician's Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1246

    03/13/2015

    Enhancing Efficacy of Chemotherapy in Triple-Negative/Basal-Like Breast Cancers by Targeting Macrophages: A Phase Ib/II Study of PLX3397 and Eribulin in Patients with Metastatic Breast Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    VICCTHO1443

    03/11/2015

    A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane?) as Maintenance Treatment after Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Sarcoma

    VICCSAR1483

    02/26/2015

    SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients with Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas

    Molecular Targeted Agents / Immunotherapy / Biologics

    Melanoma

    VICCMEL1471

    02/04/2015

    A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Melanoma

    VICCMEL1457

    01/19/2015

    A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations

    Molecular Targeted Agents / Immunotherapy / Biologics

    Prostate

    VICCURO1473

    01/09/2015

    A Randomized Phase II Study of Androgen Deprivation Therapy with or without PD 0332991 in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer.

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    VICCTHO1478

    11/14/2014

    A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Pediatric Lymphoma

    COGANHL12P1

    10/20/2014

    A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117

    Molecular Targeted Agents / Immunotherapy / Biologics

    VICCPHI1436

    08/18/2014

    A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination with Paclitaxel in Patients with Advanced Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Prostate

    VICCURO1450

    08/13/2014

    PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1430

    08/12/2014

    A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia

    VICCHEM1423

    08/08/2014

    A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

    Molecular Targeted Agents / Immunotherapy / Biologics

    Bladder
    Colon
    Esophageal
    Gastric/Gastroesophageal
    Neuro-Oncology
    Ovarian
    Urologic
    Uterine

    VICCMD1403

    06/02/2014

    An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

    Molecular Targeted Agents / Immunotherapy / Biologics

    VICCPHI1375

    05/16/2014

    Phase I Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies BVD-523-01

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1391

    04/24/2014

    A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician's Choice in Previously-Treated, HER2-Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lymphoma

    VICCHEM13105

    04/09/2014

    A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast - Female

    VICCBREP1363

    03/21/2014

    A Phase Ib/II, Multicenter, Study of the Combination of LEE011 and BYL719 with Letrozole in Adult Patients with Advanced ER+ Breast Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Pancreatic

    VICCGI1370

    12/30/2013

    A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast - Female
    Breast - Male

    ECOGBRES1207

    10/31/2013

    Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1320

    08/16/2013

    A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination with Either Docetaxel or Paclitaxel in Patients with HER2-Negative Locally Recurrent or Metastatic Breast Cancer or Non-Small Cell Lung Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Neuroendocrine
    Pancreatic

    VICCGI1250

    04/09/2013

    A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBREP12116

    03/25/2013

    An Open-Label, Phase IA/IB/IIA Study of GDC-810 Single Agent or in Combination With Palbociclib and/or an LHRH Agonist in Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCPHI1248

    10/12/2012

    An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lymphoma

    VICCHEM1146

    08/14/2012

    Ofatumumab in Combination with High Dose Cytarabine Chemoimmunotherapy for Patients with Newly Diagnosed Mantle Cell Lyjmphoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Neuroblastoma (Pediatrics)
    Pediatric Solid Tumors

    VICCPED1249

    08/06/2012

    An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    VICCTHN1244

    07/25/2012

    Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    CTSUBRENB-43-M

    04/26/2012

    A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    CTSUNSABPBREB-47-M

    04/26/2012

    A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer 

    Molecular Targeted Agents / Immunotherapy / Biologics

    Non Small Cell

    ECOGTHO5508-M

    02/09/2011

    Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

    Molecular Targeted Agents / Immunotherapy / Biologics

    Liver

    CTSUGIC80802-M

    12/07/2010

    Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung

    CTSUTHOC30607-M

    02/17/2010

    ARandomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Head/Neck

    ECOGHNE1305-M

    02/11/2009

    A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Non Small Cell

    ECOGTHOE1505-M

    07/27/2007

    A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)


    Print this page for your doctor